Polyene antifungal agent
Candida albicans Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis,
Induces membrane permeability by forming complexes with ergosterol located in fungal membranes, leading to intracellular leakage and cell death.
Concentration dependant fungicidal effects in Candida spp.
Absorption: Nystatin is not absorbed to any significant extent following oral, cutaneous, or vaginal administration
Distribution: No distribution studies have been published on nystatin
Metabolism: No data available
Elimination: No elimination studies have been published on nystatin due to its primary use in topical indications
Gastrointestinal: Nausea, vomiting, diarrhea (following PO administration)
Dermatologic: Rare case reports of contact dermatitis, and skin eruptions have been reported
Topical: Powder 50 Million Units/10g, Cream 100,000 Units/g, Ointment, Oral pastilles 200,000 Units
Suspension: 100,000 Units/ml
Vaginal tablets: 100,000 Units
Oral candidiasis: Swish and swallow 4-6mL (400,000 to 600,000 Units) PO four times daily
Topical: Apply cream or ointment two to three times daily to affected areas, OR apply topical powder to affected area two to three times daily
Vaginal infections: Insert 1 vaginal tablet into vagina at bedtime nightly x 14 days.
Oral candidiasis: Using dropper, apply 1 mililiter to each buccal membrane (total of 2 milliliters OR 200,000 units) four times daily.
Oral candidiasis: Swish and swallow 4-6mL (400,000 to 600,000 Units) PO four times daily
Renal Failure: No data available
Hepatic failures: No data available
Contraindications: Hypersensitivity to nystatin
Precautions: None
None are known
Category C: Risk unknown. Human studies inadequate.
Improvement in fungal infection by oral plaques, or topical improvement if applied for yeast infections of the skin
Bio-Statin – Bio-Tech Pharma;
Mycostatin® - Bristol-Myers Squibb
Nystop® - Paddock Labs
Pedi-Dri® - Pedinol
Nystatin Cream – Various manufacturers
Nystatin Ointment – Various manufacturers